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ABSTRACT
Objective: To evaluate the reliability of concurrent
flare identification using 3 methods (patient,
rheumatologist and Disease Activity Score (DAS)28
criteria), and construct validity of candidate items
representing the Outcome Measures in Rheumatology
Clinical Trials (OMERACT) RA Flare Core Domain Set.
Methods: Candidate flare questions and legacy
measures were administered at consecutive visits to
Canadian Early Arthritis Cohort (CATCH) patients
between November 2011 and November 2014. The
American College of Rheumatology (ACR) core set
indicators were recorded. Concordance to identify
flares was assessed using the agreement coefficient.
Construct validity of flare questions was examined:
convergent (Spearman’s r); discriminant (mean
differences between flaring/non-flaring patients); and
consequential (proportions with prior treatment
reductions and intended therapeutic change postflare).
Results: The 849 patients were 75% female, 81%
white, 42% were in remission/low disease activity (R/
LDA), and 16–32% were flaring at the second visit.
Agreement of flare status was low–strong (κ’s 0.17–
0.88) and inversely related to RA disease activity level.
Flare domains correlated highly (r’s≥0.70) with each
other, patient global (r’s≥0.66) and corresponding
measures (r’s 0.49–0.92); and moderately highly with
MD and patient-reported joint counts (r’s 0.29–0.62).
When MD/patients agreed the patient was flaring, mean
flare domain between-group differences were 2.1–3.0;
36% had treatment reductions prior to flare, with
escalation planned in 61%.
Conclusions: Flares are common in rheumatoid
arthritis (RA) and are often preceded by treatment
reductions. Patient/MD/DAS agreement of flare status
is highest in patients worsening from R/LDA.
OMERACT RA flare questions can discriminate between
patients with/without flare and have strong evidence of
construct and consequential validity. Ongoing work will
identify optimal scoring and cut points to identify RA
flares.
INTRODUCTION
People living with rheumatoid arthritis (RA)
frequently experience transient increases in
joint pain, swelling, and other symptoms
such as stiffness and fatigue that indicate
increased inflammation and worsening of
their RA.1 2 These episodes vary widely in
frequency, duration, and intensity. They can
be severe and disabling.1 3 Patients and
rheumatologists (MDs) often use the word
‘flare’ to describe such episodes. Flares are
generally expected to be reversible, though
elevated RA disease activity persists in some
cases.
Flares become clinically relevant when they
are of sufficient intensity and duration to
suggest that current therapy may be inad-
equate and a change in treatment may be
required to optimise disease management.4 5
There is growing evidence of the importance
Key messages
▸ Flares are common in rheumatoid arthritis (RA)
and are often preceded by treatment reductions.
▸ Patients and MDs generally agree when patients
flare, especially when previously in remission/
low disease activity.
▸ OMERACT RA flare questions show evidence of
reliability and construct, discriminant and conse-
quential validity.
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of identifying and addressing inflammatory flare epi-
sodes as they may contribute substantially to worsening
cardiovascular comorbidity, joint damage and other
long-term outcomes.6 Although flares can occur unex-
pectedly, the risk of flare increases when RA treatments
are tapered or withdrawn.7 In clinical trials, early identi-
fication of clinically important RA worsening would
signal the need for (re)initiation of therapy. In clinical
practice, early identification and resolution of flares
would reduce the risks associated with persistently active
disease to improve long-term outcomes.
Thus, there is a need for criteria and tools that can be
used to reliably identify and quantify RA flares that rep-
resent clinically important worsening. Several methods
have been proposed including a priori specified
increases in disease activity scores (DASs),8 9 but there is
little consensus. We are unaware of any reports that
evaluate the reliability of flare identification which repre-
sents clinically important worsening by comparing differ-
ent perspectives (eg, patients, treating rheumatologists,
use of DAS worsening criteria). Similarly, a validated
method to quantify flares remains elusive.
We have previously described our pathway to create a
consensus-based definition of RA flares and identify the
domains essential to include in any measure of flare. In
brief, the Outcome Measures in Rheumatology Clinical
Trials (OMERACT) RA Flare Group defined RA flares as
episodes of increased RA disease activity accompanied
by worsening symptoms, functional impacts, and clinical
indicators of sufficient magnitude and duration to place
individuals at greater risk of joint damage and poorer
outcomes when left untreated. Our foundational qualita-
tive and quantitative work with patients, clinicians and
other scientists identified essential domains that could
be used to measure flare severity.4 10 At OMERACT
2012, our RA Flare Core Domain Set was ratified by 200
+ OMERACT attendees.11 The RA Flare Core Set
included the American College of Rheumatology (ACR)
RA core set12 (patient and physician assessment of
disease, tender and swollen joints, acute-phase reactants,
physical function, pain) and added fatigue, stiffness and
participation. Exploration of self-management as a con-
textual factor13 and other research domains (systemic
features, coping, sleep and emotional distress) was also
endorsed.
The next steps needed to create a reliable tool to
measure RA flare are to (1) identify candidate items to
measure each RA flare domain; (2) evaluate the reliabil-
ity of flare identification from different perspectives; and
(3) assess the construct validity of our candidate flare
items assessing each flare domain.11 To identify items,
we reviewed conceptual models and existing patient-
reported outcomes (PROs)14 and collaborated with
members from the International Classification of
Function and Health framework.15 16 Here, we present
initial evidence of the reliability of flare identification
and the construct validity of the candidate OMERACT
RA flare items.
METHODS
Study participants
Data are from a subset of patients with RA seen over the
first 2 years of follow-up in the Canadian Early Arthritis
Cohort (CATCH) study, a prospective observational
study of patients with early RA recruited at 19 centres
across Canada initiated in January 2007.17 CATCH
patients are followed every 3 months in year 1, and every
6 months in year 2 using a standardised protocol.
Treatment generally follows Canadian guidelines for RA
management.18 19 At each visit, patients complete vali-
dated measures of RA symptoms and function, the treat-
ing rheumatologist performs a physical examination to
assess disease activity, and blood is drawn for analysis at
local laboratories. Ethics boards at each centre approved
the study, and written informed consent was obtained.
In November 2011, the candidate OMERACT flare
questions were added to each visit. Here, we included all
patients who met the 1987 ACR or 2010 ACR/European
League Against Rheumatism (EULAR) criteria and had
completed flare questions at ≥2 visits through November
2014. Data from the two most recent visits 3 months
apart were used; when not available, data from the two
most recent visits 6 months apart were selected (desig-
nated as V1 and V2).
Measures
Flare questions
Patients were asked whether their disease had worsened,
remained the same or improved in the past week
(7-point scale; much worse to much better) and if they
were experiencing a flare of their RA (yes/no). Patients
who classified themselves as flaring then rated the sever-
ity (11-point Numerical Rating Scale (NRS)) and dur-
ation (1–3, 4–7, 7–14 and >14 days) of their flare. All
respondents then completed the candidate OMERACT
RA Flare Core Domain Set items rating pain, physical
function, fatigue, stiffness and participation over the
past week due to RA using 11-point NRS (see online
supplementary figure 1) and indicated tender and
swollen joints on a 40-joint homunculus.20
Legacy PROs
Participants also completed the RAND-12,21 Rheumatoid
Arthritis Disease Activity Index (RADAI)22 and Work
Productivity and Activity Impairment-Rheumatoid
Arthritis (WPAI-RA) Questionnaire.23
RA Indicators
ACR core set measures were recorded, including pain
(10 cm Visual Analogue Scale (VAS)), physical function
(Health Assessment Questionnaire-Disability Index
(HAQ-DI)),24 patient and MD global assessments, MD
tender and swollen joint counts (0–28), erythrocyte sedi-
mentation rate (ESR) and C reactive protein (CRP); a
DAS28 was calculated.
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Classification of flare status reflecting clinically important
worsening
Patient definition
Individuals who answered ‘yes’ to the question ‘Are you
having a flare of your RA at this time?’ were classified as
flaring.
MD definition
Physicians were asked: ‘Do you think your patient is in a
flare today?’ (0 not in flare; 10 severe flare). Receiver
operating curves were examined to establish the cut
point which best reflected endorsement of flare (see
online supplementary figures 2A–C).
DAS28 definition
As compared with the first of selected paired visits (V1),
DAS28 worsening at the second visit (V2; ≥1.2 or
≥0.6 units if DAS28 at V1 was ≥3.2) was used to identify
flares consistent with a definition used in recent
studies.8 25 26
Statistical analysis
Distributions were examined, and descriptive statistics
were calculated. As data were missing for MD flare
and DAS28 measures on some individuals, we used t
tests to compare sociodemographic and RA character-
istics between groups with and without complete
data.
Reliability
Concordance between patient, MD and DAS28 identifi-
cation of flares at V2 was assessed using the agreement
coefficient.27 We hypothesised there would be moder-
ate–high agreement (using Cohen’s criteria)28 of flare
status between patients, MDs and DAS28.
Construct validation
To examine convergent validity, we used Spearman’s cor-
relation coefficient to estimate the degree to which
scores from flare domain questions correlated with each
other, ‘legacy’ PROs measuring similar domains, and MD
and patient-reported joint counts at V1. We hypothesised
there would be moderate (r’s≥0.30) to high correlations
(r’s≥0.50) between legacy PROs for flare questions asses-
sing pain, function, participation, fatigue and stiffness;
and weak (r’s≥0.10) to moderate correlations between
pain and MD joint counts. We selected patients with
good control of their RA at the V1 (ie, DAS28<3.2), and
calculated the difference (95% CIs) in mean change
scores at V2 in flare item scores, disease activity indicators
and patient ratings of RA activity. We hypothesised that as
compared with those not in flare at V2, flaring patients
would have significantly higher scores on flare items and
rate their RA as worse/much worse. Consequential valid-
ity was examined by evaluating the proportion of patients
with treatment reductions at V1 and rheumatologist
intention to escalate therapy at V2. Analyses were per-
formed using SAS V9.3 (SAS Institute); p values <0.05
were considered statistically significant and all tests were
two sided.
RESULTS
These analyses include data from 849 patients (see
figure 1). The sociodemographic and RA characteristics
of patients included in these analyses were similar to
those who had completed <2 flare assessments (data not
shown).
As shown in table 1, patients were mostly female,
white and 57% were in remission or low disease activity
(LDA). At V2, MD flare ratings were available for 85%
(718/849), and DAS28 scores were available for 61%
Figure 1 Flow diagram for
patient selection. CATCH,
Canadian Early Arthritis Cohort;
RA, rheumatoid arthritis.
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(515/849 – the remaining 39% had missing ESR).
Groups that were missing MD flare ratings or DAS28
scores did not differ from those with these data available
on sociodemographic or RA characteristics, suggesting
data could be treated as missing at random (see online
supplementary table S1 for additional characteristics).
Reliability: agreement of flare status
At the second visit, 201/849 (24%) of patients classified
themselves as flaring; MDs rated 233/718 (32%) and
DAS classified 84/515 (16%) as flaring. Agreement of
flare status varied based on disease activity level at the
second visit. In patients previously in remission, agree-
ment was high (κ’s≥0.73) between patients and physi-
cians and patients and DAS28 (table 2). For patients in
LDA, agreement was moderate–strong between patients
and physicians and patients and DAS (κ’s=0.44–0.63),
but agreement was low for those in moderate–high
disease activity (κ’s=0.17–0.35).
Construct validity of flare domains
At V2, OMERACT RA flare domain questions correlated
highly with each other (r’s 0.70–0.90; see online
supplementary table S2) and with patient global (r’s
0.66–0.88), and moderately with patient joint counts (r’s
0.39–0.62; table 3).
Convergent validity
Across the three flare definitions used, correlations of
OMERACT RA flare domain questions with other PROs
assessing similar constructs were high, with most >0.60
(see online supplementary table S2). Low–moderate cor-
relations were observed between pain and MD/patient
tender joint counts in flaring patients (r’s 0.29–0.48).
Known groups
At V2, mean scores for flare questions, other PROs and
RA clinical indicators were significantly higher in
patients who self-identified as flaring (table 4).
Differences between groups were highest when patients
and MD rated the patient as flaring. Patients who self-
identified as flaring or also were rated by their doctors
as flaring were much more likely (p<0.0001) to rate
their RA as worse or much worse since the previous visit.
Consequential validity
Similarly, patient flare severity ratings and change in
DAS28 scores at V2 were highest when patients and MDs
agreed the patient was flaring (p’s=0.028 and <0.001,
Table 1 Characteristics of participants by flare status
Flare classification
Patient (n=849) MD (n=718) DAS28 (n=515)
Variable mean (SD) or n (%)
unless otherwise stated
All
(n=849)
Yes
(n=201)
No
(n=648)
Yes
(n=233)
No
(n=485)
Yes
(n=84)
No
(n=431)
Sociodemographic characteristics
Age (years) 54.3 (15.4) 53.7 (14.3) 54.4 (15.7) 54.9 (15.0) 53.6 (15.4) 55.0 (15.5) 54.7 (14.5)
Female sex 635 (75%) 149 (74%) 486 (75%) 168 (72%) 365 (75%) 61 (73%) 308 (71%)
White 690 (81%) 154 (77%) 536 (83%) 181 (78%) 385 (79%) 69 (82%) 357 (83%)
Education ≤ high school 342 (40%) 95 (47%) 247 (38%) 104 (45%) 172 (35%) 32 (38%) 174 (40%)
Currently smoking ≤
2 years
140 (17%) 39 (20%) 101 (16%) 37 (16%) 81 (17%) 17 (20%) 60 (14%)
Duration in study (months;
median IQR)
18 (15) 18 (15) 18 (15) 12 (18) 18 (12) 21 (12) 18 (15)
RA characteristics
DAS28 3.2 (1.6) 3.7 (1.7) 3.0 (1.5) 3.9 (1.7) 2.7 (1.4) 2.8 (1.2) 3.2 (1.7)
Remission 277 (44%) 44 (30%) 233 (49%) 55 (30%) 182 (51%) 40 (48%) 199 (46%)
Low 83 (13%) 14 (10%) 69 (14%) 16 (9%) 59 (17%) 20 (24%) 49 (11%)
Moderate 182 (29%) 57 (39%) 125 (26%) 68 (37%) 91 (26%) 21 (25%) 120 (28%)
High 82 (13%) 30 (21%) 52 (11%) 44 (24%) 23 (6%) 3 (4%) 63 (15%)
MD tender joints (28) 3.2 (5.0) 4.9 (5.8) 2.7 (4.6) 5.4 (6.2) 2.2 (3.9) 2.1 (3.7) 3.7 (5.6)
MD swollen joints (28) 2.2 (4.1) 3.2 (4.7) 1.9 (3.9) 4.1 (5.5) 1.2 (2.6) 1.5 (3.6) 2.7 (4.8)
ESR (mm/h) 17.2 (17.4) 18.4 (18.1) 16.8 (17.2) 21.0 (20.0) 15.4 (16.1) 19.3 (20.6) 16.7 (16.7)
CRP (mg/L) 6.5 (10.5) 8.3 (12.8) 6.0 (9.6) 8.6 (11.8) 5.3 (8.8) 7.7 (11.2) 6.1 (9.0)
HAQ (0–3) 0.51 (0.60) 0.75 (0.67) 0.44 (0.55) 0.66 (0.63) 0.42 (0.56) 0.47 (0.59) 0.49 (0.60)
MD global (10 cm VAS) 1.9 (2.5) 2.8 (2.9) 1.6 (2.3) 3.2 (2.9) 1.2 (1.9) 1.3 (1.8) 2.0 (2.6)
Patient global (10 cm VAS) 3.4 (2.9) 4.6 (3.1) 3.0 (2.8) 4.2 (3.0) 2.9 (2.8) 2.7 (2.7) 3.4 (3.0)
Pain (10 cm VAS) 3.2 (2.8) 4.3 (3.0) 2.8 (2.6) 4.0 (2.9) 2.7 (2.7) 2.8 (2.7) 3.2 (2.9)
Sociodemographic characteristics are at enrolment; RA characteristics are at first of paired visits. At second visit, 718 patients had a second
MD rating of flare and 515 had a DAS28-ESR at both visits; missing DAS28 values are due to missing ESR.
CRP, C reactive protein; DAS, Disease Activity Score; ESR, erythrocyte sedimentation rate; HAQ, Health Assessment Questionnaire; RA,
rheumatoid arthritis; VAS, Visual Analogue Scale.
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Table 2 Agreement of flare status between patient, MD and DAS28 worsening criteria by disease activity level
Patient Agreement
Flare classification (Visit 2) Flare status Yes No Observed Expected (%) AC1 κ
MD flare classification (n=718)
All Yes 98 (58%) 135 (25%) 512 (71%) 59 0.52
No 71 (42%) 414 (75%)
Remission Yes 5 (23%) 39 (16%) 212 (79%) 78 0.73
No 17 (77%) 207 (84%)
Low disease activity Yes 8 (50%) 17 (29%) 49 (66%) 59 0.44
No 8 (50%) 41 (71%)
Moderate disease activity Yes 37 (69%) 40 (45%) 86 (60%) 49 0.21
No 17 (31%) 49 (55%)
High disease activity Yes 23 (79%) 11 (65%) 29 (63%) 56 0.35
No 6 (21%) 6 (35%)
DAS28 criterion flare classification (n=515)
All ≥1.2/0.6 36 (31%) 48 (12%) 388 (75%) 69 0.64
<1.2/0.6 79 (69%) 352 (88%)
Remission ≥1.2/0.6 0 (0%) 1 (0%) 232 (89%) 89 0.88
<1.2/0.6 27 (100%) 232 (100%)
Low disease activity ≥1.2/0.6 2 (13%) 7 (12%) 54 (73%) 72 0.63
<1.2/0.6 13 (87%) 52 (88%)
Moderate disease activity ≥1.2/0.6 21 (40%) 33 (36%) 80 (56%) 53 0.17
<1.2/0.6 31 (60%) 59 (64%)
High disease activity ≥1.2/0.6 13 (62%) 7 (44%) 22 (59%) 51 0.20
<1.2/0.6 8 (38%) 9 (56%)
AC, agreement coefficient; DAS, Disease Activity Score.
Table 3 Relationship between items assessing OMERACT RA Flare domains and other measures by flare status*
Patient Physician DAS28†
Domains All Yes No Yes No Yes No
N Source 849 201 648 233 485 84 431
Pain
How much pain due to RA in past week HAQ 0.91 0.89 0.89 0.91 0.90 0.88 0.89
Today’s level of pain today RADAI 0.87 0.86 0.81 0.84 0.84 0.84 0.86
Pain past week – 0.92 0.91 0.88 0.92 0.89 0.93 0.91
Joint area pain severity (0–48) RADAI 0.71 0.55 0.67 0.58 0.70 0.44 0.72
Patient tender joint count (28) Patient 0.62 0.36 0.57 0.48 0.58 0.48 0.61
MD tender joint count (28) MD 0.49 0.29 0.42 0.36 0.42 0.36 0.46
Physical function
Disability score (0–3) HAQ 0.76 0.73 0.68 0.74 0.70 0.74 0.74
Physical function RAND-12 −0.65 −0.62 −0.58 −0.59 −0.64 −0.61 −0.68
Daily activities in past 7 days WPAI 0.77 0.67 0.74 0.75 0.76 0.69 0.77
Fatigue
Vitality (RAND-12) RAND-12 −0.63 −0.58 −0.59 −0.70 −0.59 −0.69 −0.65
Unusual fatigue/tiredness past week – 0.86 0.86 0.83 0.85 0.85 0.84 0.87
Participation
Role—physical RAND-12 −0.71 −0.69 −0.63 −0.67 −0.69 −0.72 −0.72
Social function RAND-12 −0.61 −0.61 −0.54 −0.67 −0.61 −0.72 −0.67
Productivity while working WPAI 0.78 0.73 0.70 0.77 0.73 0.71 0.77
RA affecting daily activities WPAI 0.77 0.70 0.73 0.76 0.78 0.81 0.76
Stiffness
Morning Joint Stiffness Score RADAI 0.69 0.51 0.66 0.57 0.67 0.58 0.69
*Spearman correlation coefficients for second visit.
†DAS28 scores <3.2 at second visit required an increase of 1.2 units whereas DAS≥3.2 at second visit required increase of 0.6 units to
classify flare.
DAS, Disease Activity Score; HAQ, Health Assessment Questionnaire; OMERACT, Outcome Measures in Rheumatology Clinical Trials; RA,
rheumatoid arthritis; RADAI, Rheumatoid Arthritis Disease Activity Index; RAND-12, RAND 12 Health Survey; WPAI, Work Productivity and
Activity Impairment.
Bykerk VP, et al. RMD Open 2016;2:e000225. doi:10.1136/rmdopen-2015-000225 5
Rheumatoid arthritis
group.bmj.com on July 5, 2016 - Published by http://rmdopen.bmj.com/Downloaded from 
respectively; see table 5). RA treatment had been
reduced or stopped in 36% (10/28), and 61% of rheu-
matologists reported an intention to increase treatment
in response to flare.
DISCUSSION
This is the first study to evaluate the reliability of concur-
rent flare identification in RA using three methods:
patient reports, physician ratings and DAS28 criteria
used in recent reduction/withdrawal trials. Agreement
about flares using the three methods (patient, MD and
DAS) was highest for patients initially in remission and
LDA. Our data are also the first to show the construct
validity of the five candidate OMERACT RA flare
domains (pain, fatigue, stiffness, function and participa-
tion). These data support additional evaluation of our
patient-centered tool in treatment studies to establish
numerical criteria for flare for use in trial and practice.
Agreement about flares varied and was influenced by
disease activity level at the initial visit. Others have also
reported that the patient and physician do not always
agree about RA status, including flares.3 29–31 We found
that agreement was highest between physician-based
measures, either by MD report or DAS worsening, and
patients, when disease activity had been in good control
at the preceding visit. Conversely, agreement regarding
flares was lowest between rheumatologists and DAS28
criteria when patients had previously been in moderate–
high disease activity levels. This may, in part, reflect
greater uncertainty in identifying worsening of disease
when disease activity is already high. Also, in our study,
the mean worsening in DAS28 of flaring patients was
nearly two points higher, which is considerably greater
than DAS criteria. It is not surprising that the least reli-
able method of identifying flare was the DAS criteria
definition (identifying flare as ‘worsening’ of DAS28
that exceeded measurements error (0.6 units) or twice
its value).32 This definition has been used in only a few
studies that evaluated RA flares in the context of taper-
ing or withdrawing trials.8
Our results support the construct, discriminant and
consequential validity of the five candidate items captur-
ing the OMERACT RA Flare Domain Core Set. Flare
domain questions correlated highly with PROs measur-
ing similar constructs that are widely used in RA trials
and were able to discriminate between patients with/
without flare using three definitions. In people who
were flaring at the second visit (but not the first), indi-
vidual flare question scores were significantly higher,
and similar increases were observed in other PROs as
well as clinical indicators of RA disease activity. In con-
trast, there was little change in scores of non-flaring
patients over these visits. Finally, in flaring patients, 61%
of rheumatologists indicated they intended to intensify
treatment indicating evidence of the consequential valid-
ity of flare identification and consistent with sufficient
clinical worsening to justify escalation in therapy.
Table 4 Change in flare question scores and other RA indicators in patients previously in remission/low disease activity
Patient flare*
Characteristic
(mean SD)
Yes
N=58
No
N=302
Difference
(95% CI)/
p value
Patient and
MD flare
N=28
Patient and MD
no flare
N=219
Difference
(95% CI)/p value
OMERACT flare domain questions (0–10)
Pain 1.7 (2.4) −0.4 (1.8) 2.0 (1.4 to 2.7) 2.3 (2.6) −0.5 (1.7) 2.7 (1.7 to 3.8)
Stiffness 1.3 (3.0) −0.3 (1.7) 1.6 (0.8 to 2.4) 2.1 (3.1) −0.4 (1.7) 2.5 (1.3 to 3.7)
Function 1.6 (2.7) −0.3 (1.9) 1.9 (1.2 to 2.6) 1.8 (2.7) −0.4 (1.8) 2.2 (1.1 to 3.2)
Fatigue 0.6 (3.1) −0.3 (2.1) 0.9 (0.1 to 1.8) 1.6 (3.0) −0.5 (1.9) 2.1 (0.9 to 3.3)
Participation 1.5 (2.7) −0.3 (1.8) 1.8 (1.1 to 2.5) 1.8 (2.7) −0.4 (1.6) 2.2 (1.1 to 3.3)
Patient global 1.9 (3.0) −0.3 (2.1) 2.2 (1.3 to 3.0) 2.6 (2.8) −0.3 (2.2) 3.0 (2.1 to 3.9)
Physician measures
MD global (0–10) 1.2 (2.3) −0.1 (1.3) 1.3 (0.7 to 2.0) 2.7 (2.1) −0.3 (1.2) 3.0 (2.1 to 3.8)
MD TJC28* 2.8 (4.5) 0.3 (2.4) 2.4 (1.2 to 3.7) 4.8 (5.5) 0.2 (1.9) 4.6 (2.4 to 6.7)
MD SJC28† 1.6 (4.0) 0.0 (1.4) 1.6 (0.5 to 2.7) 3.4 (5.0) −0.1 (1.2) 3.6 (1.6 to 5.5)
Acute-phase reactants
CRP (mg/L) 3.0 (11.0) 0.1 (5.9) 2.9 (−0.2 to 6.1) 5.8 (15.0) −0.1 (5.6) 5.9 (−0.4 to 12.1)
ESR (mm/h) 4.3 (11.6) 0.6 (8.7) 3.7 (0.4 to 7.0) 6.3 (14.1) 0.4 (8.5) 5.9 (0.2 to 11.5)
RA transition (since previous visit) (n (%))
Much worse/worse 9 (16%) 5 (2%) <0.0001 6 (21%) 3 (1%) <0.0001
Slightly worse/same/
slightly better
41 (71%) 179 (59%) 22 (79%) 128 (58%)
Better/much better 8 (14%) 118 (39%) 0 (0%) 88 (40%)
*Tender joint count.
†Swollen joint count.
CRP, C reactive protein; ESR, erythrocyte sedimentation rate; OMERACT, Outcome Measures in Rheumatology Clinical Trials;
RA, rheumatoid arthritis.
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The five RA flare items represent patient-reported
core domains identified by patients and providers as
essential to measure for RA flare beyond the patient
global assessment of disease activity.10 The high rates of
agreement identifying flares between patients and physi-
cians are not unexpected. The flare questions were
developed to reflect the usual interchange of informa-
tion between patients and physicians when discussing
disease worsening. Concordance was lowest between
patients and DAS-rated and MD-rated flare status when
patients were in moderate or high disease activity at the
first visit. One reason for this may be that the DAS cri-
teria do not directly incorporate any of the specific
domains identified by patients and providers as essential
to measuring RA flare, with the exception of patient
global. While we found that patient global scores were
highly correlated with the five RA Flare domain scores,
it is unclear whether patient global alone can be used to
identify flares related to inflammation. Notably, only two
of the five domains, pain and physical function, are cap-
tured in the ACR RA core set, and core set measures
make up standard composite measures of disease activity
derived to measure improvement. RA composite mea-
sures alone may not be sensitive or specific to inflamma-
tory flare, underscoring the need for a tool that can
reliably identify and quantify RA flares.
Our results showed that agreement about flare status
was high between patients and providers; also, the
largest increases in flare domain scores and DAS28
occurred in flaring patients when there was patient/MD
concordance if the patient was flaring. Better under-
standing of the factors related to discordance in flare
reports between the patient and doctor assessments
warrant additional study. In the interim, however, an
important finding of our work for clinicians is recogni-
tion that patients can reliably identify significant
increases in inflammatory activity, and that most of the
time clinicians agree with patients when patients state
they are in a flare. This is especially true in patients that
had been in remission or LDA at a previous visit.
While doctors and patients may not always agree on
flare status, agreement between both increases confi-
dence that RA flares, which truly reflect worsening
inflammation, can be reliably detected. A means to reli-
ably identify and precisely quantify inflammatory flares
in RA is needed for clinical trials where drug therapy is
reduced or withdrawn as well as comparative effective-
ness trials. In this large observational ‘real-world’ trial,
rheumatologists classified 32% of patients as flaring, and
treatment had been reduced/stopped at the prior visit
in 36% of patients confirming that therapeutic change is
an important antecedent to flare in many patients. As
evidence grows that tight control is essential to improve
long-term outcomes,33 early identification and treatment
of flares seem essential to improve long-term outcomes.
The ability to quickly and easily identify flares
Table 5 Flare characteristics as classified by patients, MD and patient–MD concordant reports in patients with RA who were
previously in remission/low disease activity (n=360)
Characteristics (mean (SD) or n (%))
Patient
N=58 (16%)
MD
N=71 (20%)
Patient and MD
N=28 (8%)
Patient flare severity (0–10) 4.4 (2.1) 4.5 (2.6) 5.0 (2.3)
Duration (days)
1–3 12 (21%) 5 (18%) 5 (18%)
4–7 6 (10%) 4 (14%) 4 (14%)
8–14 12 (21%) 6 (21%) 6 (21%)
>14 28 (48%) 13 (46%) 13 (46%)
Change in DAS28
DAS28 at time of flare 3.2 (1.4) 3.0 (1.4) 3.9 (1.4)
DAS28 at previous visit 2.1 (0.7) 2.1 (0.6) 2.1 (0.7)
Worsening of DAS28 1.1 (1.4) 0.9 (1.3) 1.8 (1.2)
Change in DMARD# and/or oral steroids use from previous visit
Reduced (dose or frequency) 22 (38%) 29 (41%) 9 (32%)
Stopped (without escalating or adding another therapy) 19 (33%) 28 (39%) 7 (25%)
Reduced and/or stopped 24 (41%) 34 (48%) 10 (36%)
MD intent to increase treatment* 25 (45%) 37 (53%) 17 (61%)
Proposed treatment change*
Non-methotrexate DMARDS added 9 (16%) 10 (14%) 7 (25%)
Methotrexate added or increased† 2 (6%) 3 (7%) 1 (7%)
Biologics added/switched (not due to side effect) 2 (3%) 3 (4%) 2 (7%)
Steroids added (PO/IM or IA; not used in prior visit) 7 (12%) 7 (10%) 4 (14%)
NSAIDs added (not used in the prior visit) 3 (5%) 3 (4%) 2 (7%)
DMARDs could include biologic and synthetic DMARDs.
*Reported increase in treatment at second or subsequent visit.
†Dose increased or changed from oral to subcutaneous.
DAS, Disease Activity Score; DMARD, disease-modifying antirheumatic drug; IA, intra-articular; IM, intramuscular; NSAIDs, non-steroidal
anti-inflammatory drugs; PO, per os.
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incorporating the patient perspective of flare could also
facilitate more patient-centred care through the rapid
identification of patients potentially requiring escalation
of therapy between scheduled visits. Early flare identifi-
cation enabled by patient report may also help patients
know when to initiate additional self-management
strategies.
Strengths of this study include the prospective collec-
tion of flare data in the context of a national observa-
tional study of early RA where many clinical and PROs
were systematically collected in a standardised manner.
Our sample included patients with all levels of disease
activity. Foundational work closely followed OMERACT
methods for developing new measurement tools and
COSMIN criteria to ensure high methodological
quality.16 34–36 However, there are limitations. We did not
a priori provide guidance or a definition of flare for
patients and physicians, and the threshold identified by
ROC curves to optimise discrimination of flare was low.
Providing a standardised definition and querying physi-
cians directly (yes/no) about flare status may increase
agreement. Nevertheless, for patients initially under
good control, agreement regarding flares was strong.
PRO measures are evolving, especially for fatigue, stiff-
ness and participation.37 The ability to differentiate
patients who are flaring or not was at the group level;
additional work is needed to identify whether the ques-
tions can be used to reliably identify individuals who are
flaring. Worsening assessed by patients and providers
was at a single point in time; we did not specifically ask
if judgements were made in relation to a previous time
period (eg, 3 months), an approach being used by
others.3 DAS28 criteria reflect changes from the previ-
ous visit, either 3 or 6 months prior. We have no infor-
mation about symptoms, function, self-management (eg,
transient use of glucocorticoids or non-steroidal anti-
inflammatory drugs), and limited information on poten-
tial treatment changes between visits.
These initial results support the usefulness of the
OMERACT RA flare questions for identifying flare.
Additional evaluation is needed before they can be
recommended for widespread use. Work is ongoing by
our group to develop a scoring system for the
OMERACT flare questions and to evaluate unidimen-
sionality, responsiveness, and to identify clear thresholds
that reflect worsening of RA inflammation signalling a
potential need to intensify treatment. Flare data are
being collected in international observational studies
and randomised controlled trials (RCTs) of early and
established RA to help establish criteria for symptom
intensity and duration necessary to define inflammatory
flare, and to develop thresholds for existing disease activ-
ity measures. Identifying and understanding the role of
self-management strategies and other contextual factors
also need to be considered.13 Further exploration of dis-
cordance between doctors and patients regarding RA
flares and evaluation of patient and MD joint counts is
also ongoing.
In conclusion, in routine rheumatology care settings,
flares in RA representing clinically important worsening
of inflammation are common and are often preceded by
treatment reductions. Agreement about flare status
among patients, treating rheumatologists, and using
DAS28 criteria is high, especially for patients previously
in remission or LDA. The five questions that represent
the OMERACT RA Flare Core Domain Set, where
patients are asked to rate their pain, fatigue, stiffness,
function and participation have strong evidence of
content validity, known groups and consequential valid-
ity. Additional work is also ongoing to develop a scoring
system and identify the thresholds of change and flare
severity that can be used by clinicians and researchers in
order to reliably identify flares using the OMERACT RA
flare questions.
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